Summary
Global Markets Direct’s, ‘Obsessive-Compulsive Disorder - Pipeline Review, H1 2016’, provides an overview of the Obsessive-Compulsive Disorder pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Obsessive-Compulsive Disorder, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Obsessive-Compulsive Disorder and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Obsessive-Compulsive Disorder
- The report reviews pipeline therapeutics for Obsessive-Compulsive Disorder by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Obsessive-Compulsive Disorder therapeutics and enlists all their major and minor projects
- The report assesses Obsessive-Compulsive Disorder therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Obsessive-Compulsive Disorder
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Obsessive-Compulsive Disorder
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Obsessive-Compulsive Disorder pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
AbbVie Inc.
Addex Therapeutics Ltd
Amorsa Therapeutics Inc.
C4X Discovery Limited
Novartis AG
Omeros Corporation
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Obsessive-Compulsive Disorder Overview 6
Therapeutics Development 7
Pipeline Products for Obsessive-Compulsive Disorder - Overview 7
Pipeline Products for Obsessive-Compulsive Disorder - Comparative Analysis 8
Obsessive-Compulsive Disorder - Therapeutics under Development by Companies 9
Obsessive-Compulsive Disorder - Therapeutics under Investigation by Universities/Institutes 10
Obsessive-Compulsive Disorder - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Obsessive-Compulsive Disorder - Products under Development by Companies 14
Obsessive-Compulsive Disorder - Products under Investigation by Universities/Institutes 15
Obsessive-Compulsive Disorder - Companies Involved in Therapeutics Development 16
AbbVie Inc. 16
Addex Therapeutics Ltd 17
Amorsa Therapeutics Inc. 18
C4X Discovery Limited 19
Novartis AG 20
Omeros Corporation 21
Obsessive-Compulsive Disorder - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Target 23
Assessment by Mechanism of Action 25
Assessment by Route of Administration 27
Assessment by Molecule Type 28
Drug Profiles 29
18-MC - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
ADX-71743 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
ADX-88178 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
fluvoxamine maleate - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
mavoglurant - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
OMS-527 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Small Molecules for Autism Spectrum Disorders and Obsessive Compulsive Disorders - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Small Molecules for Obsessive-Compulsive Disorder - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Small Molecules to Antagonize Orexin-1 Receptor for CNS Disorders - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Small Molecules to Inhibit DAT and SERT for CNS Disorders - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Obsessive-Compulsive Disorder - Recent Pipeline Updates 40
Obsessive-Compulsive Disorder - Dormant Projects 43
Obsessive-Compulsive Disorder - Discontinued Products 44
Obsessive-Compulsive Disorder - Product Development Milestones 45
Featured News & Press Releases 45
Mar 19, 2013: Omeros Elucidates Mechanism Of PDE7 Inhibitors In Addiction 45
Aug 02, 2007: Jazz Pharmaceuticals, Inc. Announces Submission of Complete Responses to FDA Approvable Letters for Luvox 45
Appendix 46
Methodology 46
Coverage 46
Secondary Research 46
Primary Research 46
Expert Panel Validation 46
Contact Us 46
Disclaimer 47
List of Tables
Number of Products under Development for Obsessive-Compulsive Disorder, H1 2016 7
Number of Products under Development for Obsessive-Compulsive Disorder - Comparative Analysis, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Number of Products under Investigation by Universities/Institutes, H1 2016 10
Comparative Analysis by Late Stage Development, H1 2016 11
Comparative Analysis by Clinical Stage Development, H1 2016 12
Comparative Analysis by Early Stage Development, H1 2016 13
Products under Development by Companies, H1 2016 14
Products under Investigation by Universities/Institutes, H1 2016 15
Obsessive-Compulsive Disorder - Pipeline by AbbVie Inc., H1 2016 16
Obsessive-Compulsive Disorder - Pipeline by Addex Therapeutics Ltd, H1 2016 17
Obsessive-Compulsive Disorder - Pipeline by Amorsa Therapeutics Inc., H1 2016 18
Obsessive-Compulsive Disorder - Pipeline by C4X Discovery Limited, H1 2016 19
Obsessive-Compulsive Disorder - Pipeline by Novartis AG, H1 2016 20
Obsessive-Compulsive Disorder - Pipeline by Omeros Corporation, H1 2016 21
Assessment by Monotherapy Products, H1 2016 22
Number of Products by Stage and Target, H1 2016 24
Number of Products by Stage and Mechanism of Action, H1 2016 26
Number of Products by Stage and Route of Administration, H1 2016 27
Number of Products by Stage and Molecule Type, H1 2016 28
Obsessive-Compulsive Disorder Therapeutics - Recent Pipeline Updates, H1 2016 40
Obsessive-Compulsive Disorder - Dormant Projects, H1 2016 43
Obsessive-Compulsive Disorder - Discontinued Products, H1 2016 44
List of Figures
Number of Products under Development for Obsessive-Compulsive Disorder, H1 2016 7
Number of Products under Development for Obsessive-Compulsive Disorder - Comparative Analysis, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Comparative Analysis by Early Stage Products, H1 2016 13
Assessment by Monotherapy Products, H1 2016 22
Number of Products by Targets, H1 2016 23
Number of Products by Stage and Targets, H1 2016 23
Number of Products by Top 10 Mechanism of Actions, H1 2016 25
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 25
Number of Products by Stage and Top 10 Routes of Administration, H1 2016 27
Number of Products by Stage and Top 10 Molecule Types, H1 2016 28
